Merck to buy Terns Pharmaceuticals in $6.7B deal

Merck's $6.7 billion acquisition of Terns Pharmaceuticals signals the beginning of Big Pharma's most consequential patent cliff scramble since Lipitor lost exclusivity. The deal, announced Wednesday at $53 per share — a mere 6% premium to Tuesday's close — underscores a brutal reality: when you're staring at a $25 billion annual revenue decline from Keytruda patent expiration, you pay market price for quality assets, and you pay it now [1].

Terns' stock climbed six-fold over the prior six months on the strength of TERN-701, a leukemia candidate with blockbuster potential. That run-up meant Merck couldn't extract deal terms from a position of strength. The company paid full freight, accepting a premium that barely qualifies as one. This is not opportunistic M&A — this is strategic necessity [1].

The transaction values Terns at approximately $6.7 billion total enterprise value, positioning TERN-701 as Merck's lead pipeline asset to backfill oncology revenue ahead of Keytruda's looming patent expiration. For institutional capital, the question is not whether Merck needed to act, but whether $6.7 billion represents the floor or ceiling for pre-commercial oncology assets in 2026.

The Keytruda Cliff Reshapes Valuation Discipline

Merck disclosed the acquisition on March 25, 2026, with closing expected later this year subject to regulatory clearance. The pharma giant structured the deal as a straightforward cash buyout, eliminating earnout structures or contingent value rights that typically characterize biotech M&A when acquirers want downside protection [1].

That tells you everything about Merck's conviction level — and desperation. Keytruda generated approximately $25 billion in revenue in 2024, representing roughly 40% of Merck's total sales. Patent expiration begins in 2028 for certain indications, with full erosion expected by 2030. The company needs multiple multi-billion-dollar revenue streams in development yesterday. TERN-701 checks that box, but at a cost structure that reflects zero negotiating leverage [1].

According to Adam Feuerstein, STAT's senior biotech columnist, Terns became an "attractive takeover target" precisely because of TERN-701's blockbuster trajectory [1]. The asset targets acute myeloid leukemia (AML), a market where current standard-of-care drugs face efficacy and safety limitations. If TERN-701 demonstrates superiority in Phase 3 trials, peak sales could exceed $3 billion annually. That would imply Merck paid roughly 2.2x peak sales — reasonable for a late-stage oncology asset, but only if Phase 3 execution is flawless.

The risk lies in the narrow premium. A 6% premium to the prior close means the market had already priced in acquisition probability. Terns shareholders captured most of the deal value during the six-month run-up, not at announcement. For Merck, this means the strategic rationale is fully transparent to the market: they needed the asset, and Terns knew it.

Why This Deal Reprices the Oncology M&A Market

Merck's willingness to pay full market value for a Phase 2/3 asset resets expectations for every biotech with a credible oncology pipeline. If Terns commanded $6.7 billion with TERN-701 still in mid-to-late stage development, comparable assets will now anchor valuations to this transaction.

Consider the broader M&A environment. On the same day as the Terns announcement, Gilgamesh Pharma closed a $60 million financing round to advance its psychedelics and neuroscience pipeline [2]. That financing, while significant for a specialty pharma play, represents less than 1% of what Merck paid for Terns. The valuation gap between neuro and oncology has widened further. Institutional capital continues to flow disproportionately toward cancer therapeutics, where regulatory pathways are more established and commercial infrastructure is mature.

The market is also drawing comparisons to other recent oncology M&A. While specific comps from 2025 are not disclosed in available sources, the Terns deal sits comfortably within the historical range for late-stage oncology acquisitions. What's notable is the absence of a control premium. In a typical M&A scenario, acquirers pay 30-50% above the unaffected share price. Merck paid 6%. That suggests Terns was either overvalued heading into the announcement, or Merck extracted zero value from the negotiation.

Our read: Terns held all the cards. With multiple strategic buyers likely circling — and the threat of going it alone with a successful Phase 3 readout — Terns' board had no incentive to accept a discounted offer. Merck's urgency to secure the asset ahead of Keytruda's patent cliff forced the company to accept market terms.

The Oncology Pipeline Imperative and Institutional Implications

For institutional investors, the Terns acquisition clarifies several investment theses. First, Big Pharma's willingness to pay full price for late-stage oncology assets means late-stage biotech valuations have a floor. Venture and growth equity investors can underwrite exits with greater confidence, knowing strategic buyers will pay market multiples when necessity overrides valuation discipline.

Second, the deal confirms that oncology remains the highest-conviction therapeutic area for M&A. Despite growing interest in obesity, neuroscience, and rare disease, cancer therapeutics continue to command the largest deal values. Terns' $6.7 billion buyout exceeds most recent transactions in other therapeutic areas, reinforcing oncology's premium status.

Third, the narrow premium signals that biotech boards have regained negotiating power. The 2022-2023 downturn created a buyer's market, with Big Pharma extracting favorable deal terms. That dynamic has reversed. Quality assets now trade at or above market value, with minimal acquisition premiums. For PE and VC investors, this means exit timing matters less than asset quality. If the science is compelling, strategic buyers will pay up regardless of market conditions.

The Terns deal also highlights the increasing importance of patent cliff management. Merck is not alone in facing revenue erosion from patent expiration. Bristol Myers Squibb faces a similar dynamic with Eliquis, and AbbVie continues to navigate life after Humira. Each of these companies will pursue tuck-in acquisitions to refill pipelines. The result: sustained demand for late-stage assets, compressed acquisition premiums, and elevated valuations across the biotech sector.

Institutional allocators should note that this dynamic benefits late-stage biotechs with credible data, not early-stage platforms. Merck paid $6.7 billion for a Phase 2/3 asset with clear line-of-sight to commercialization. Earlier-stage assets, by contrast, continue to face valuation pressure. The barbell effect is real: late-stage oncology commands premium multiples, while preclinical and Phase 1 assets struggle to attract capital.

Cross-Sector M&A Acceleration Amid Patent Cliffs

The Terns acquisition is part of a broader M&A acceleration across healthcare and adjacent sectors. While the primary catalyst is Merck's Keytruda patent expiration, other large-cap pharma and biotech companies face similar pressures. This creates a favorable environment for M&A activity, with strategic buyers deploying capital aggressively to secure pipeline assets.

For PE investors, the implication is clear: healthcare M&A multiples are rising, and late-stage assets are increasingly expensive. Firms that underwrote investments at 2023-2024 valuations may see compression in returns as acquisition multiples normalize upward. Conversely, firms with exposure to late-stage oncology assets stand to benefit from Merck's willingness to pay full price.

The deal also underscores the importance of data quality. Terns' six-fold stock price appreciation over six months reflects investor confidence in TERN-701's clinical profile. For institutional investors, this reinforces the need for rigorous scientific diligence. In an environment where strategic buyers pay full market multiples, the delta between success and failure lies in clinical execution, not deal timing.

The Plocamium View

Merck's Terns acquisition is less a deal than a bellwether. The 6% premium is not a negotiating outcome — it's an admission that Big Pharma has lost pricing power in late-stage oncology M&A. When a company facing a $25 billion revenue cliff accepts market terms for a mid-stage asset, every biotech CEO and every VC takes note.

Here's what the market is missing: this deal doesn't just reset oncology valuations — it establishes a new floor for any late-stage asset with credible data in a high-value therapeutic area. Terns traded at full value before the announcement, meaning Merck's premium was entirely in the deal certainty, not the price. That's a fundamental shift. Strategic buyers are no longer extracting value through M&A. They're simply securing assets before competitors do.

The second-order effect is more significant. If Merck, one of the largest and most sophisticated pharma acquirers, cannot negotiate a meaningful discount on a $6.7 billion deal, smaller strategic buyers have zero leverage. That means late-stage biotech valuations are now set by the public markets, not by M&A negotiations. The implication for institutional capital: biotech equity is the M&A trade now. If you can buy a quality late-stage asset in the public markets, you're effectively front-running the strategic buyer at the same price they'll pay.

The risk, of course, is clinical failure. Merck is betting $6.7 billion that TERN-701 succeeds in Phase 3. If it doesn't, the company will have overpaid by several billion dollars. But Merck doesn't have a choice. The Keytruda cliff is real, and the company cannot afford to wait for discounted assets. This is the definition of strategic urgency overriding valuation discipline.

For allocators, the playbook is clear: identify late-stage oncology assets with credible data, buy them in the public markets, and wait for the strategic buyer to emerge. The Terns deal proves that strategic buyers will pay full price. The only variable is clinical success.

The Bottom Line

Merck's $6.7 billion Terns acquisition confirms that Big Pharma's patent cliff scramble has begun in earnest, and late-stage oncology assets will trade at full market value. The 6% premium is not a discount — it's a signal that strategic buyers have lost negotiating leverage. For institutional investors, this creates a clear opportunity: late-stage biotech equity is now the M&A arbitrage trade, with strategic buyers willing to pay full multiples for quality assets.

The Keytruda cliff is Merck's problem today. It will be every large-cap pharma's problem tomorrow. That means sustained demand for late-stage oncology assets, compressed acquisition premiums, and elevated valuations across the sector. Quality assets with credible data will command premium multiples. Everything else will struggle. Position accordingly.

---

References [1] Adam Feuerstein, "Merck to buy Terns Pharmaceuticals in $6.7B deal," STAT, March 25, 2026. [2] Kyle LaHucik, "Gilgamesh's psychedelics pipeline gets $60M backing after AbbVie deal," Endpoints News, March 25, 2026.